Gerresheimer's business model thrives on close partnerships with pharmaceutical giants, crafting tailor-made solutions for diverse therapeutic areas. A comprehensive transformation program is being implemented, including cost reductions, operational improvements, and a new segmentation starting in 2026. The company is preparing to carve out and sell the Moulded Glass business, with new leadership in place.
Cyborg Score Rationale
Shares fell 11% after the company cut its 2025 guidance for the third time this year. Gerresheimer AG's solvency score is 32/100. The company faces significant operational challenges and restructuring, though market fundamentals remain sound for pharmaceutical packaging.
Top Insights
In 2024, Gerresheimer AG's revenue was 2.04 billion, an increase of 2.28% compared to the previous year's 1.99 billion.
Company issued multiple guidance cuts in 2025, signaling operational and market headwinds that undermine investor confidence
Strategic transformation includes business carve-outs and operational restructuring to improve efficiency and prepare divisions for independence
International footprint of production facilities allows for high-quality, efficient manufacturing and distribution, supporting the company's commitment to innovation and meeting regulatory requirements across regions.
Named Competitors
Pharmaceutical Packaging & Drug Delivery — Primary competitor in pharma glass packaging and drug delivery systems
Pharmaceutical Packaging — Competitor in glass and plastic pharmaceutical packaging solutions
Recent Developments
(October 2025) Third guidance cut for 2025; expecting organic revenue decline of 2-4%
(November 2025) Uwe Röhrhoff appointed as interim CEO to replace Dietmar Siemssen
(October 2025) External investigation initiated into revenue recognition from bill-and-hold agreements
Open the full interactive Gerresheimer AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.